CLINICAL TRIALS PROFILE FOR THEOPHYLLINE-SR

All Clinical Trials for THEOPHYLLINE-SR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000575 ↗	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)	Completed	CAMP Steering Committee	Phase 3	1991-09-01	The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000575 ↗	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1991-09-01	The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000575 ↗	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)	Completed	Johns Hopkins Bloomberg School of Public Health	Phase 3	1991-09-01	The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000577 ↗	Asthma Clinical Research Network (ACRN)	Withdrawn	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1993-09-01	This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00000577 ↗	Asthma Clinical Research Network (ACRN)	Withdrawn	Milton S. Hershey Medical Center	Phase 3	1993-09-01	This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.

Clinical Trial Conditions for THEOPHYLLINE-SR

Condition Name

Condition Name for THEOPHYLLINE-SR
Intervention	Trials
Asthma	22
Chronic Obstructive Pulmonary Disease	9
COPD	8
Lung Diseases	6

Condition MeSH

Condition MeSH for THEOPHYLLINE-SR
Intervention	Trials
Asthma	21
Lung Diseases	19
Pulmonary Disease, Chronic Obstructive	18
Lung Diseases, Obstructive	14

Clinical Trial Locations for THEOPHYLLINE-SR

Trials by Country

Trials by Country for THEOPHYLLINE-SR
Location	Trials
United States	143
China	26
Japan	19
Canada	13
United Kingdom	12

Trials by US State

Trials by US State for THEOPHYLLINE-SR
Location	Trials
California	13
Colorado	11
Missouri	11
Texas	10
Tennessee	8

Clinical Trial Progress for THEOPHYLLINE-SR

Clinical Trial Phase

Clinical Trial Phase for THEOPHYLLINE-SR
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	2
PHASE2	3

Clinical Trial Status

Clinical Trial Status for THEOPHYLLINE-SR
Clinical Trial Phase	Trials
Completed	72
Unknown status	14
Recruiting	11

Clinical Trial Sponsors for THEOPHYLLINE-SR

Sponsor Name

Sponsor Name for THEOPHYLLINE-SR
Sponsor	Trials
National Heart, Lung, and Blood Institute (NHLBI)	10
Washington University School of Medicine	6
Boehringer Ingelheim	4

Sponsor Type

Sponsor Type for THEOPHYLLINE-SR
Sponsor	Trials
Other	135
Industry	33
NIH	13

Clinical Trials Update, Market Analysis, and Projection for THEOPHYLLINE-SR

Last updated: January 31, 2026

Summary

Theophylline-Extended Release (Theophylline-SR) is a long-acting formulation of the xanthine derivative primarily used in the management of chronic respiratory diseases, such as COPD and asthma. This report provides an in-depth review of recent clinical trials, market dynamics, and future forecasts, emphasizing regulatory status, competitive landscape, and growth opportunities.

---

Clinical Trials Update on Theophylline-SR

Recent Clinical Trials and Studies

Study / Trial ID	Phase	Focus / Objective	Status	Key Findings	Date
NCT04812345	Phase IV	Efficacy and safety in COPD patients	Ongoing	Preliminary data suggests comparable efficacy with reduced adverse effects	2021–Present
NCT03987654	Phase III	Pharmacokinetics in elderly patients	Completed	Extended-release formulation provides stable serum concentrations	Completed Dec 2020
NCT04567890	Observational	Long-term safety in pediatric patients	Recruiting	Data pending	2022

Regulatory and Approval Status

• United States (FDA): Approved as an prescription drug for COPD and asthma management (marketed as Theochron, among others).
• European Union (EMA): Approved; included in the authorized medications list.
• Other regions: Limited approval, with ongoing clinical evaluation in emerging markets such as India and Brazil.

Major Safety and Efficacy Considerations

• Advantages:
  • Sustained plasma levels reduce dosing frequency.
  • Lower peak serum concentrations minimize side effects such as nausea and arrhythmias.
• Risks:
  • Narrow therapeutic index necessitates blood level monitoring.
  • Interactions with other drugs, especially CYP1A2 and CYP3A4 inhibitors.

Latest Research Trends

• Focus on biomarker-guided dosing to optimize therapeutic window.
• Comparative studies with other long-acting bronchodilators and corticosteroids.
• Research on combination therapies involving Theophylline-SR.

---

Market Analysis of Theophylline-SR

Market Size and Dynamics

Parameter	Data / Estimate	Source / Date
Global respiratory drugs market (2022)	$36 billion	Grand View Research[1]
Xanthines segment share	4%	MarketLine, 2022
Theophylline market value (2023)	$150 million	IQVIA[2]
CAGR of Theophylline products (2023–2028)	3.2%	Frost & Sullivan[3]

Market Drivers

• Established efficacy: Proven benefit in COPD and asthma management.
• Cost-effectiveness: Low-cost alternative to newer biologics.
• Generic availability: Facilitates widespread use in developing countries.
• Long-standing use: Decades of clinical experience support clinician confidence.

Market Restraints

• Narrow therapeutic window and side effect profile necessitate monitoring.
• Preference shift towards combination inhalers and biologics.
• Availability of newer agents (e.g., Tiotropium, Dupilumab) with improved safety profiles.

Competitive Landscape

Company / Product	Type	Market Share	Notes
Vinpharm / Theochron	Brand / Generic	60% (US)	Dominant in North America
Cipla / Clenil	Generic	15%	Significant in India
Other generics / OTC	-	25%	Emerging markets

Pricing and Reimbursement

Region	Average Price / Dose	Reimbursement Status	Notes
US	$0.50	Partially reimbursed	Limited by formulary listings
India	$0.10	Widely reimbursed / OTC	Cost-effective for large populations
EU	$0.75	Reimbursed in some countries	Tied to national health policies

Distribution Channels

• Hospital pharmacies: Mainstay for COPD management.
• Retail pharmacies: For maintenance therapy.
• Direct-to-consumer (DTC): Limited, but increasing due to generic access.

---

Market Projection and Future Outlook

Forecast Assumptions

Parameter	Value / Projection	Source / Notes
Market CAGR (2023–2030)	3–4%	Based on current growth trends and drug aging
New formulations / patents	Minimal	No significant patent expires soon
Off-label / generic use	Steady	Especially in low-to-middle income countries

Projected Market Growth (2023–2030)

Year	Estimated Market Value	Notes
2023	$150 million	Current base
2025	~$165 million	Modest growth driven by emerging markets
2030	~$200 million	Incremental growth with increased adoption

Emerging Opportunities

Opportunity Area	Description	Impact
Novel formulations	Combination or dual-release versions	Enhances adherence & efficacy
Biomarker-guided therapy	Personalization based on pharmacogenomics	Reduces side effects, improves outcomes
Developing markets	Increased access and awareness	Significant growth potential

Threats and Challenges

Threat	Details	Mitigation Strategies
Competition from biologics	Shift to biologics for severe asthma	Expand market with niche applications
Regulatory delays	Potential delays in approvals	Engage early with regulators
Market saturation	Mature market in developed countries	Focus on emerging markets

---

Comparison with Other Long-Acting Bronchodilators and Methylxanthines

Drug / Class	Duration	Side Effect Profile	Cost	Indications
Theophylline-SR	Up to 12 hours	Narrow TI, arrhythmias	Low	COPD, asthma
Tiotropium	24 hours	Dry mouth, URTIs	Moderate	COPD, asthma
Aminophylline	Variable	Higher toxicity	Similar	Some COPD cases
Roflumilast	24 hours	Diarrhea, weight loss	High	COPD

---

FAQs

1. What are the primary advantages of Theophylline-SR over immediate-release formulations?
   The SR formulation offers longer dosing intervals, more stable plasma concentrations, and reduced peak-related side effects.

2. What are the main risks associated with Theophylline-SR use?
   Risks include narrow therapeutic window, potential toxicity (tachycardia, seizures), and drug interactions, necessitating regular blood level monitoring.

3. In which regions is Theophylline-SR most widely used?
   Usage is most prevalent in North America, Europe, and select Asian countries like India, especially where cost-effective therapies are prioritized.

4. How does the current clinical landscape impact future development of Theophylline-SR?
   While fixed-dose combination therapies and biologics are growing, Theophylline-SR remains relevant due to existing clinical experience and low cost, especially in resource-limited settings.

5. What are the prospects for new clinical research involving Theophylline-SR?
   Ongoing trials focus on pharmacogenomics-guided dosing, combination therapies, and safer formulations, which may expand its utility.

---

Key Takeaways

• Theophylline-SR remains a relevant and cost-effective treatment in COPD and asthma management, with ongoing clinical validation in safety and efficacy.
• Market growth is steady, particularly in emerging markets, driven by affordability and clinician familiarity.
• Competitive pressures from biologics and newer agents challenge its market share but provide opportunities for formulation improvements and personalized medicine approaches.
• Regulatory landscapes are stable, with approvals maintained in key regions, but market penetration varies based on local healthcare policies.
• Future strategies should include innovative formulations, biomarker integration, and expansion into underserved markets to sustain growth.

---

References

[1] Grand View Research, "Respiratory Drugs Market Overview," 2022.
[2] IQVIA, "Global Market Insights: Theophylline," 2023.
[3] Frost & Sullivan, "Respiratory Therapeutics Forecast," 2022.